Australia Dermatology Drugs Market Analysis Report [2022-30] I Insights10

Australia Dermatology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Australia dermatology drugs market will reach a value of $516 Mn from $204 Mn in 2022, growing at a CAGR of 12.3% during 2022-2030. The market is primarily dominated by local players such as Faulding, Bioscience International, Aspen Pharmacare, and Alpha pharm. The market is driven by an aging population, disparities in universal health coverage, and the launch of new and innovative drugs. The dermatology drug market in Australia is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel.

ID: IN10AUPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Australia AUTHOR: Dr. Vishwa Modhia

Buy Now

Australia Dermatology Drugs Market Analysis Summary

By 2030, it is anticipated that the Australia dermatology drugs market will reach a value of $516 Mn from $204 Mn in 2022, growing at a CAGR of 12.3% during 2022-2030.

In Australia, dermatology is a recognized and well-established branch of medicine, with many skilled practitioners offering patients top-notch care. In the field of medicine known as dermatology, diseases of the skin, hair, and nails are identified and treated. Australia's 2019 health spending per person was $5427, or 9.9% of the country's GDP.

Since 1984, Medicare, Australia's national health insurance program, has included medicines and drugs as a significant component. The Australian government is implementing coordinated care across the country in its health plans and policies, including GP-led team-based care for patients with dermatological chronic conditions.

australia dermatology drugs market analysis

Market Dynamics

Market Growth Drivers Analysis

The demand for dermatology goods and services in Australia is rising along with the private healthcare market. Professional dermatologists, skin care clinics, and aesthetic facilities are numerous. Emerging research suggests that biological agents may also treat the systemic inflammation caused by psoriasis. Biologic agents have revolutionized the treatment of psoriatic skin.

Market Restraints

Despite the universal coverage provided by the government, some patients may still have difficulty accessing care due to factors such as geographic location, waiting lists, and lack of availability of specialists in certain areas. The aging population in Australia is increasing, which is putting pressure on the healthcare system to provide care for an increasing number of older patients.

Competitive Landscape

Key Players

Alpha pharms (AUS)
Aspen Pharmacare (AUS)
Bioscience International (AUS)
Faulding (AUS)
Medical Developments International (AUS)
SDA Pharmaceuticals (AUS)
Vision Pharma (AUS)
Galderma
GlaxoSmithKline
Pfizer
Sanofi

Notable Recent Deals

July 2022: Sun Pharmaceutical Industries announced that it has broadened the scope of its collaboration with Cassiopea on acne medication. The WINLEVI (clascoterone) cream 1 percent license and supply agreements have been amended to include territory in Australia. According to the agreement, Cassiopea will grant the company the sole right to create and market WINLEVI in Japan, Australia, and New Zealand.

Healthcare Policies and Regulatory Landscape

The Therapeutic Goods Administration (TGA) is the Australian regulatory body responsible for the regulation of therapeutic goods, including drugs, medical devices, and biologicals. The TGA plays a critical role in ensuring that the therapeutic goods that are available to Australians are of an acceptable standard.

Reimbursement Scenario

The government is making medicines cheaper for Australian households. For the first time in its 75-year history, the maximum cost of general prescriptions under the Pharmaceutical Benefits Scheme (PBS) will fall. The maximum co-payment of $42.50 will drop to $30 as of January 1, 2023.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Dermatology Drugs Market Segmentation

The Dermatology Drugs Market is segmented as mentioned below

By Disease (Revenue, USD Billion):

Psoriasis
Acne Vulgaris
Atopic Dermatitis
Eczema
Rosacea
Itchthyosis
Vitiligo
Others

By Route Of Administration (Revenue, USD Billion):

Oral
Parenteral
Topical

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.